Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13582-13590
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13582
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13582
Table 3 Laboratory assessments and anti-hepatitis C virus treatments administered to patients with hepatitis C virus infection, and the responses to treatment n (%)
HCV(n = 1406) | HCV and HBV(n = 42) | |
Laboratory assessments: | ||
HCV PCR positive1 | 1366/1375 (99.3) | 38/40 (95.0) |
ALT abnormal2 | 575 (40.9) | |
AST abnormal2 | 499 (35.5) | |
AFP abnormal | 86/486 (17.7) | |
Received antiviral treatment | 936 (66.6) | 22 (52.4) |
Number of treatments | (n = 936) | (n = 23) |
First | 751 (80.2) | 20 (87.0) |
Second | 140 (15.0) | 3 (13.0) |
Third | 45 (4.8) | 0 |
Antiviral agents used in first-time antiviral treatments | (n = 750) | (n = 20) |
Interferon (IFN) | 232 (30.9) | 5 (25.0) |
PEG-IFN | 514 (68.5) | 15 (75.0) |
Ribavirin | 702 (93.6) | 15 (75.0) |
Duration of completed treatment, months (median, range) | (n = 277) | (n = 3) |
11.8 (0.1-139) | 11.9 (5-11.9) | |
Responses to treatment3 | ||
Quick response4 | 125/425 (29.4) | 4/10 (40.0) |
Early response5 | 126/349 (36.1) | 2/6 (33.3) |
Response at end of treatment6 | 38/276 (13.8) | 2/5 (40.0) |
Sustained response7 | 24/121 (19.8) | 0 |
No response | 20/276 (7.2) | 0 |
- Citation: Sun YT, Zhang YX, Tang H, Mao Q, Wang XZ, Zhang LY, Chen H, Zhong YN, Lin SM, Zhang DZ. Clinical characteristics and current management of hepatitis B and C in China. World J Gastroenterol 2014; 20(37): 13582-13590
- URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13582.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13582